Johnson & Johnson (NYSE:JNJ)

Why These 3 Biotechs More Than Doubled on Monday

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

Markets have hit new highs recently, but the main indexes were all marginally lower on Wednesday morning. With the Dow Jones industrials up over 28,000 and the S&P 500 over ...
Read Full Story »

How Dow 28,000 Can Rapidly Become Dow 30,000 and Even Higher in 2020

Investors love seeing the stock market hit new highs. It's impressive enough for the Dow Jones industrial average to have hit 28,000 and for the S&P 500 to have hit ...
Read Full Story »

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

When investors hear that the stock market just hit a new all-time high, it's probably fairly easy to assume that this means almost all the individual stocks are probably at ...
Read Full Story »

Why Goldman Sachs Enhanced Income Strategy May Be Perfect for 2020

Even though the S&P 500 now sits at all-time highs after over 10 years of a bull market, the venerable index still offers a 1.9% dividend yield and 6% expected ...
Read Full Story »

J&J Gets $10 Billion Gift as Lab Results Show No Asbestos in Baby Powder

Johnson & Johnson (NYSE: JNJ) has found itself involved in more controversy than the company would prefer to see. The consumer and health products company has been dogged in the ...
Read Full Story »

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Amazon, AT&T, Comcast, Delphi, DocuSign, J&J, JPMorgan, T-Mobile, Verizon, Wells Fargo and More

Stocks were indicated to open marginally lower on Wednesday, even after overseas markets were modestly higher. Investors are having to grapple with a slower economy at the same time that ...
Read Full Story »

Johnson & Johnson Offers a Strong Start to Earnings Season

When Johnson & Johnson (NYSE: JNJ) reported its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said it had $2.12 in earnings per share (EPS) ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday. The consensus estimates are calling for $2.00 in earnings per ...
Read Full Story »

Coca-Cola, Goldman Sachs, IBM, Johnson & Johnson and More Dow Stocks Reporting This Week

Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. The Dow is hovering near its all-time high, just as this ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Stocks were indicated to open sharply higher on Brexit hopes and U.S./China trade hopes, and earnings season will kick off next week. The bull market is now well over 10 ...
Read Full Story »

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

The announcement that a jury has awarded $8 billion in damages to a man accusing Johnson & Johnson (NYSE: JNJ) of failing to warn about the side effects of ...
Read Full Story »

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Johnson & Johnson (NYSE: JNJ) surprised investors on Wednesday morning by announcing a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial. While this in and ...
Read Full Story »

Unusual Settlement Deal Proposed for Opioid Lawsuits

Five pharmaceuticals makers are proposing an unusual method for settling hundreds of the more than 2,500 lawsuits facing drugmakers that made and sold opioid painkillers. The five companies want to ...
Read Full Story »